GMAB News and Press, Genmab A/S From 04/21/23

2023-04-21 06:55:13 ET Genmab ( GMAB ) announced an award in the second arbitration arising under a license agreement with Johnson & Johnson's ( NYSE: JNJ ) unit Janssen Biotech over cancer drug daratumumab, sold as Darzalex. Genmab said the arbitral tribunal d...

Company Announcement COPENHAGEN , Denmark; April 21 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab...

2023-04-18 07:32:23 ET Genmab ( GMAB ) has reported worldwide Q1 net trade sales of $2.26B for DARZALEX (daratumumab) prescription medicine. Net trade sales were $1.91B in the U.S. and $1.07B in the rest of the world. Genmab receives royalties on the worldwide net sales of...

Company Announcement Net sales of DARZALEX ® in the first quarter of 202 3 totaled USD 2,264 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 18 , 2...

Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway Genmab A/S (Nasdaq: GMAB) and argenx (Euro...

Genmab A/S press release ( GMAB ): FY GAAP EPS of DKK83.65. Revenue of DKK14.6B (+72.2% Y/Y). Outlook: Genmab expects its 2023 revenue to be in the range of DKK 14,600–16,100 million, compared to DKK 14,595 million in 2022. Genmab’s projected revenue for 202...

Genmab A/S (GMAB) Q4 2022 Results Conference Call February 22, 2023 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Ch...

Company Announcement Repurchase of up to 2 2 0,000 shares H onoring commitments under our Restricted Stock Unit program Completion expected on March 31 , 2023 COPENHAGEN , Denmark; February 22, 20 2 3 ...

Company Announcement COPENHAGEN , Denmark; February 22, 2023 – Genmab A/S ( Nasdaq: GMAB ) announced today the publication of its Annual Report for 2022. Below is a summary of business progress in 2022, financial performance for the year an...

Summary MorphoSys AG is a German commercial-stage biopharmaceutical company founded in 1992 with more than 100+ pipeline candidates. We believe MorphoSys's two key value drivers are a) monjuvi and b) pelabresib. We expect Monjuvi's sales to continue to falter. There are no short...